CAPITAL SOLEIL 15
LOE Approachingavobenzone; ecamsule; octocrylene
NDATOPICALCREAM
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CAPITAL SOLEIL 15 (avobenzone; ecamsule; octocrylene). Approved for sunburns, wind burned, chapped lips. First approved in 2006.
Drug data last refreshed 2h ago · AI intelligence enriched 4h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAPITAL SOLEIL 15 is a topical cream containing avobenzone, ecamsule, and octocrylene, formulated as a broad-spectrum sunscreen for UV protection. It is indicated for prevention and treatment of sunburns, wind-burned skin, and chapped lips. The active ingredients function as UV filters that absorb and dissipate ultraviolet radiation.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely preparing defensive strategies and may be downsizing or consolidating functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (3)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.